Patents Represented by Attorney Sarah E. Bates
-
Patent number: 5510464Abstract: This invention provides a method to therapeutically increase perfusion in a mammal comprising administering stroma-free hemoglobin at a dose ranging from the least amount effective to increase perfusion, up to a dose of about 2500 mg per kilogram of body weight.Type: GrantFiled: May 3, 1994Date of Patent: April 23, 1996Assignee: Baxter International Inc.Inventor: Robert J. Przybelski
-
Patent number: 5453278Abstract: Improved Implant assemblies and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells. The boundary structure is laminated, combining elements having different characteristics beneficial to the survival of the implanted cells. Filaments of adhesive material lay in between the elements. The filaments of adhesive material have been melted in place by the application of heat and solidified in place by cooling to secure the elements together into a composite laminated structure.Type: GrantFiled: January 28, 1994Date of Patent: September 26, 1995Assignee: Baxter International Inc.Inventors: Eddie K. M. Chan, Robin G. Pauley, James H. Brauker, Lecon Woo
-
Patent number: 5352773Abstract: The present invention relates to a stable hemoglobin based composition having sufficiently low levels of methemoglobin to effectively function as an oxygen carrying solution upon administration to a patient made by the process comprising: a) adding an oxygenated or deoxygenated form of said blood substitute to an oxygen impermeable package, and b) storing said container at from between 5.degree. C. to 45.degree. C. for sufficient time to permit the autoreduction of methemoglobin. The stable hemoglobin based composition includes hemoglobin, modified hemoglobin and/or encapsulated hemoglobin. To effectively function as an oxygen carrying solution upon administration to a patient, the stable hemoglobin based solution cannot have greater than about 50% of said hemoglobin based solution in the methemoglobin form but, preferably no more than about 15%. The invention further relates to a method to store a stable oxygen carrying solution according to the above discussed process.Type: GrantFiled: October 16, 1992Date of Patent: October 4, 1994Assignee: Baxter International Inc.Inventors: Richard L. Kandler, John C. Spicuzza
-
Patent number: 5344454Abstract: Improved Implant assemblies and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved chamber for holding the implanted cells. The chambers include first and second wall elements and an intermediate sealing element. The first and second wall elements overlie an open area in the sealing member to form a chamber for holding cells for implantation. A sealed region is created between the wall elements and the sealing element body to close the chamber. In one arrangement, the sealed region is created by means of a sonic weld made while the implanted cells are present in the chamber. In another arrangement, the sealed region is created by means of applying an external force to compress the peripheral edges of the wall elements and the sealing element together while the implanted cells are present in the chamber.Type: GrantFiled: April 1, 1992Date of Patent: September 6, 1994Assignee: Baxter International Inc.Inventors: Robert A Clarke, Robin G. Pauley, Ronald S. Hill, James H. Brauker, Shmuel Sternberg, Daniel R. Boggs
-
Patent number: 5334706Abstract: This invention provides a method to therapeutically increase perfusion in a mammal comprising administering stroma-free hemoglobin at a dose ranging from the least amount effective to increase perfusion, up to a dose of about 2500 mg per kilogram of body weight.Type: GrantFiled: January 30, 1992Date of Patent: August 2, 1994Assignee: Baxter InternationalInventor: Robert J. Przybelski
-
Patent number: 5314471Abstract: Implant assemblies and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish a boundary between the host and the implanted cells. The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.Type: GrantFiled: April 1, 1992Date of Patent: May 24, 1994Assignee: Baxter International Inc.Inventors: James H. Brauker, Ronald S. Hill, Laura A. Martinson, Daniel R. Boggs, Robert C. Johnson
-
Patent number: 5281579Abstract: An aqueous solution of cross-linked hemoglobin free of active virus and having a P50 under physiologic conditions of at least 26 mm. Hg. are disclosed.Type: GrantFiled: November 12, 1991Date of Patent: January 25, 1994Assignee: Baxter International Inc.Inventor: Timothy N. Estep
-
Patent number: 5248766Abstract: A non-immunogenic mixture of hemoglobin based modified monomers and oligomers produced by the polymerization of a hemoglobin based solution in the presence of a three membered heterocyclic ring, i.e. polyether oxirane. The modified hemoglobin composition has a P.sub.50 of at least equivalent to the P.sub.50 of human red blood cell hemoglobin.Type: GrantFiled: April 21, 1992Date of Patent: September 28, 1993Assignee: Baxter International Inc.Inventors: Deanna J. Nelson, Ton T. Hai, Ana Srnak
-
Patent number: 5128452Abstract: A process for the production of crosslinked hemoglobin comprises crosslinking hemoglobin in the presence of sodium tripolyphosphate.Type: GrantFiled: April 19, 1989Date of Patent: July 7, 1992Assignee: Baxter International Inc.Inventors: Ton T. Hai, Deanna J. Nelson, Ana Srnak
-
Patent number: 5053453Abstract: Thromboresistant materials are disclosed comprising hirudin or hirudin derivatives covalently linked to support materials such that the resultant composition has substantially the same biological activity as hirudin. Methods for making such compositions are also disclosed.Type: GrantFiled: January 15, 1991Date of Patent: October 1, 1991Assignee: Baxter International Inc.Inventor: Cecilia S. L. Ku
-
Patent number: 5041615Abstract: Bis(salicyl) diesters useful as cross-linking agents for hemoglobin are prepared in high yield and purity by reacting salicylic acid or a derivative thereof with a lower aliphatic dicarboxylic acid halide in a lower aliphatic ketone or nitrile solvent in the presence of a pyridine derivative. The desired diester is recovered from the resulting insoluble pyridine derivative salt.Type: GrantFiled: December 5, 1989Date of Patent: August 20, 1991Assignee: Baxter International Inc.Inventors: Ton T. Hai, Deanna J. Nelson, Ana Srnak
-
Patent number: 5013866Abstract: An improved method of synthesizing 3,5-dibromosalicylic acid provides a highly purified pharmaceutical grade product free of toxic by-products and solvents. The purified product may be utilized as an intermediate in synthesizing pharmaceutical grade substances, as a bactericide when incorporated into topical ointments, and as an adjuvant in drug absorption systems.Type: GrantFiled: November 28, 1989Date of Patent: May 7, 1991Assignee: Baxter International Inc.Inventors: Ton T. Hai, Deanna J. Nelson
-
Patent number: 4935000Abstract: A method and composition of regenerating tissue. More specifically, a method for regenerating pancreatic islet tissue having the histological and insulin-containing properties of islets typically found in neonatal or adult animals is described. The regenerated islet tissue is produced by fetal mesenchyme acting upon an epithelium such that an inductive message causes the epithelium to differentiate into islet tissue.Type: GrantFiled: April 27, 1987Date of Patent: June 19, 1990Assignee: East Carolina UniversityInventor: Ronald W. Dudek
-
Patent number: 4861867Abstract: Hemoglobin solutions are purified by heating in the presence of a reducing agent or other deoxygenating conditions such that nonhemoglobin proteins are selectively precipitated and/or virus is inactivated while minimizing hemoglobin loss.Type: GrantFiled: January 23, 1989Date of Patent: August 29, 1989Assignee: Baxter International, Inc.Inventor: Timothy N. Estep
-
Patent number: 4831012Abstract: Hemoglobin solutions are purified by heating in the presence of a reducing agent or other deoxygenating conditions such that nonhemoglobin proteins are selectively precipitated and/or virus is inactivated while minimizing hemoglobin loss. For example the hemoglobin is heated in the form of deoxyhemoglobin.Type: GrantFiled: February 3, 1988Date of Patent: May 16, 1989Assignee: Baxter International Inc.Inventor: Timothy N. Estep